LFMD Valuation

LifeMD Inc

Add to Watchlist

Advanced Chart

6.430

+0.35(5.757%)1D

Overview
Forecast
Valuation
Earnings

LFMD Relative Valuation

LFMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LFMD is overvalued; if below, it's undervalued.

Historical Valuation

LifeMD Inc (LFMD) is now in the Fair zone, suggesting that its current forward PS ratio of 1.06 is considered Fairly compared with the five-year average of -15.60. The fair price of LifeMD Inc (LFMD) is between 2.77 to 12.73 according to relative valuation methord.

Relative Value

Fair Zone

2.77-12.73

Current Price：6.34

Fair

-180.42

Trailing

Forward

9.12

EV/EBITDA

LifeMD Inc. (LFMD) has a current EV/EBITDA of 9.12. The 5-year average EV/EBITDA is 5.70. The thresholds are as follows: Strongly Undervalued below -16.10, Undervalued between -16.10 and -5.20, Fairly Valued between 16.59 and -5.20, Overvalued between 16.59 and 27.49, and Strongly Overvalued above 27.49. The current Forward EV/EBITDA of 9.12 falls within the Historic Trend Line -Fairly Valued range.

61.38

EV/EBIT

LifeMD Inc. (LFMD) has a current EV/EBIT of 61.38. The 5-year average EV/EBIT is -29.34. The thresholds are as follows: Strongly Undervalued below -205.89, Undervalued between -205.89 and -117.61, Fairly Valued between 58.94 and -117.61, Overvalued between 58.94 and 147.22, and Strongly Overvalued above 147.22. The current Forward EV/EBIT of 61.38 falls within the Overvalued range.

1.06

LifeMD Inc. (LFMD) has a current PS of 1.06. The 5-year average PS is 1.33. The thresholds are as follows: Strongly Undervalued below -0.76, Undervalued between -0.76 and 0.29, Fairly Valued between 2.38 and 0.29, Overvalued between 2.38 and 3.42, and Strongly Overvalued above 3.42. The current Forward PS of 1.06 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

LifeMD Inc. (LFMD) has a current P/OCF of 0.00. The 5-year average P/OCF is 4.26. The thresholds are as follows: Strongly Undervalued below -19.35, Undervalued between -19.35 and -7.55, Fairly Valued between 16.06 and -7.55, Overvalued between 16.06 and 27.86, and Strongly Overvalued above 27.86. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

LifeMD Inc. (LFMD) has a current P/FCF of 0.00. The 5-year average P/FCF is 38.52. The thresholds are as follows: Strongly Undervalued below -301.28, Undervalued between -301.28 and -131.38, Fairly Valued between 208.42 and -131.38, Overvalued between 208.42 and 378.32, and Strongly Overvalued above 378.32. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

LifeMD Inc (LFMD) has a current Price-to-Book (P/B) ratio of -153.61. Compared to its 3-year average P/B ratio of -81.65 , the current P/B ratio is approximately 88.13% higher. Relative to its 5-year average P/B ratio of -263.57, the current P/B ratio is about -41.72% higher. LifeMD Inc (LFMD) has a Forward Free Cash Flow (FCF) yield of approximately 6.28%. Compared to its 3-year average FCF yield of -6.75%, the current FCF yield is approximately -193.03% lower. Relative to its 5-year average FCF yield of -12.36% , the current FCF yield is about -150.80% lower.

-153.61

P/B

Median3y

-81.65

Median5y

-263.57

6.28

FCF Yield

Median3y

-6.75

Median5y

-12.36

Competitors Valuation Multiple

The average P/S ratio for LFMD's competitors is 1.02, providing a benchmark for relative valuation. LifeMD Inc Corp (LFMD) exhibits a P/S ratio of 1.06, which is 4.31% above the industry average. Given its robust revenue growth of 22.81%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Oncology Institute Inc

Performance Decomposition

Market capitalization of LFMD increased by 16.03% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -17.10 to -29.85.

The secondary factor is the Revenue Growth, contributed 22.81%to the performance.

Overall, the performance of LFMD in the past 1 year is driven by P/E Change. Which is more unsustainable.

22.81%

50.66M → 62.22M

Revenue Growth

-81.33%

-13.50 → -2.52

Margin Expansion

74.55%

-17.10 → -29.85

P/E Change

16.03%